Cancer statistics: Breast cancer in situ

CA Cancer Journal for Clinicians

Volumn 65, Issue 6, 2015, Pages 481-495

  Ward, Elizabeth M ^a   Desantis, Carol E ^a   Lin, Chun Chieh ^a   Kramer, Joan L ^b   Jemal, Ahmedin ^a   Kohler, Betsy ^c   Brawley, Otis W ^a   Gansler, Ted ^a  

^a AMERICAN CANCER SOCIETY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c North American Association of Central Cancer Registries   (United States)

Author keywords

breast neoplasms; ductal carcinoma in situ; epidemiology; lobular carcinoma in situ; lobular neoplasia; race ethnicity specific incidence

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; RALOXIFENE; TAMOXIFEN;

ARTICLE; BILATERAL CANCER; BREAST BIOPSY; BREAST CALCIFICATION; BREAST CANCER; BREAST DENSITY; BREAST EXAMINATION; BREAST RECONSTRUCTION; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CANCER STATISTICS; CARCINOMA IN SITU; DISEASE SURVEILLANCE; FAMILY HISTORY; HUMAN; INCIDENTAL FINDING; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LOBULAR CARCINOMA IN SITU; MAMMOGRAPHY; MASTECTOMY; PARTIAL MASTECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK REDUCTION; UNITED STATES; ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; FEMALE; INCIDENCE; MIDDLE AGED; PATHOLOGY; REGISTER; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; REGISTRIES; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84947048022     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21321     Document Type: Article

References (93)

1. Morrow M, Schnitt SJ, Norton L., Current management of lesions associated with an increased risk of breast cancer. Nat Rev Clin Oncol. 2015; 12: 227-238.
2. Partridge AH, Elmore JG, Saslow D, McCaskill-Stevens W, Schnitt SJ., Challenges in ductal carcinoma in situ risk communication and decision-making: report from an American Cancer Society and National Cancer Institute workshop. CA Cancer J Clin. 2012; 62: 203-210.
3. Elmore JG, Fenton JJ., Ductal carcinoma in situ (DCIS): raising signposts on an ill-marked treatment path. J Natl Cancer Inst. 2012; 104: 569-571.
4. Hanahan D, Weinberg RA., Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-674.
5. Surveillance, Epidemiology and End Results (SEER) Program. SEER Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence-CiNA Analytic File, 1995-2011, Custom File With County, NAACCR. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2015.
6. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Stat Database: Incidence-SEER 13 Regs Research Data (with SEER Delay Factors), Nov 2013 Sub (1992-2011) -Linked To County Attributes-Total US, 1969-2012 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2014.
7. Surveillance Research Program, National Cancer Institute. SEER Stat Software. Version 8.2.1. Bethesda, MD: National Cancer Institute; 2015.
8. Statistical Methods and Applications Branch, Surveillance Research Program, National Cancer Institute. Joinpoint Regression Program. Version 4.2.0.2. Bethesda, MD: Statistical Methods and Applications Branch, Surveillance Research Program, National Cancer Institute; 2015.
9. Kim HJ, Fay MP, Feuer EJ, Midthune DN., Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000; 19: 335-351.
10. Fritz A, Percy C, Jack A, et al, eds. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
11. Li CI, Malone KE, Saltzman BS, Daling JR., Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer. 2006; 106: 2104-2112.
12. Lakhani S, Ellis I, Schnitt S, Tan P, van de Vijver M., WHO Classification of Tumours of the Breast. 4th ed. Lyon, France: International Agency for Research on Cancer; 2012.
13. Allred DC., Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr. 2010; 2010: 134-138.
14. Erbas B, Provenzano E, Armes J, Gertig D., The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006; 97: 135-144.
15. Sanders ME, Schuyler PA, Dupont WD, Page DL., The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005; 103: 2481-2484.
16. Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ., Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer. 2005; 103: 1778-1784.
17. Eusebi V, Feudale E, Foschini MP, et al., Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol. 1994; 11: 223-235.
18. Sanders ME, Schuyler PA, Simpson JF, Page DL, Dupont WD., Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up. Mod Pathol. 2015; 28: 662-669.
19. Hughes LL, Wang M, Page DL, et al., Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009; 27: 5319-5324.
20. Kantor O, Winchester DJ., Breast conserving therapy for DCIS-does size matter? J Surg Oncol. 2014; 110: 75-81.
21. Lee SK, Yang JH, Woo SY, Lee JE, Nam SJ., Nomogram for predicting invasion in patients with a preoperative diagnosis of ductal carcinoma in situ of the breast. Br J Surg. 2013; 100: 1756-1763.
22. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2015. Fort Washington, PA: NCCN; 2015.
23. Jain RK, Mehta R, Dimitrov R, et al., Atypical ductal hyperplasia: interobserver and intraobserver variability. Mod Pathol. 2011; 24: 917-923.
24. Schnitt SJ, Connolly JL, Tavassoli FA, et al., Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol. 1992; 16: 1133-1143.
25. Elmore JG, Longton GM, Carney PA, et al., Diagnostic concordance among pathologists interpreting breast biopsy specimens. JAMA. 2015; 313: 1122-1132.
26. Wang SY, Shamliyan T, Virnig BA, Kane R., Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Breast Cancer Res Treat. 2011; 127: 1-14.
27. College of American Pathologists. Protocol for the Examination of Specimens From Patients With Ductal Carcinoma in Situ (DCIS) of the Breast. Version 3.2.0.0. cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/cp-breast-dcis-13protocol-3200.pdf. Accessed March 21, 2015.
28. Bland KI., William Hunter Harridge Lecture: Contemporary management of pre-invasive and early breast cancer. Am J Surg. 2011; 201: 279-289.
29. Nekhlyudov L, Habel LA, Achacoso N, et al., Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS. J Natl Cancer Inst. 2012; 104: 614-621.
30. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, et al., Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010; 2010: 162-177.
31. Recht A., Are the randomized trials of radiation therapy for ductal carcinoma in situ still relevant? J Clin Oncol. 2014; 32: 3588-3590.
32. Warnberg F, Garmo H, Emdin S, et al., Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. J Clin Oncol. 2014; 32: 3613-3618.
33. Wapnir IL, Dignam JJ, Fisher B, et al., Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011; 103: 478-488.
34. Donker M, Litiere S, Werutsky G, et al., Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol. 2013; 31: 4054-4059.
35. Cuzick J, Sestak I, Pinder SE, et al., Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011; 12: 21-29.
36. McCormick B, Winter K, Hudis C, et al., RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 2015; 33: 709-715.
37. Punglia RS, Burstein HJ, Weeks JC., Radiation therapy for ductal carcinoma in situ: a decision analysis. Cancer. 2012; 118: 603-611.
38. Clarke M, Collins R, Darby S, et al., Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 366: 2087-2106.
39. Hwang ES., The impact of surgery on ductal carcinoma in situ outcomes: the use of mastectomy. J Natl Cancer Inst Monogr. 2010; 2010: 197-199.
40. Virnig BA, Tuttle TM, Shamliyan T, Kane RL., Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010; 102: 170-178.
41. Saslow D, Boetes C, Burke W, et al., American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007; 57: 75-89.
42. Tuttle TM, Jarosek S, Habermann EB, et al., Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol. 2009; 27: 1362-1367.
43. Hawley ST, Jagsi R, Morrow M, et al., Social and clinical determinants of contralateral prophylactic mastectomy. JAMA Surg. 2014; 149: 582-589.
44. Kruper L, Xu X, Henderson K, Bernstein L., Disparities in reconstruction rates after mastectomy for ductal carcinoma in situ (DCIS): patterns of care and factors associated with the use of breast reconstruction for DCIS compared with invasive cancer. Ann Surg Oncol. 2011; 18: 3210-3219.
45. Allred DC, Anderson SJ, Paik S, et al., Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012; 30: 1268-1273.
46. Eng-Wong J, Costantino JP, Swain SM., The impact of systemic therapy following ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010; 2010: 200-203.
47. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Risk Reduction. Version 2.2015. Fort Washington, PA: NCCN; 2015.
48. National Cancer Institute. PDQ® Breast Cancer Prevention. Bethesda, MD: National Cancer Institute; 2015. cancer.gov/types/breast/hp/breast-prevention-pdq. Accessed May 27, 2015.
49. Visvanathan K, Hurley P, Bantug E, et al., Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013; 31: 2942-2962.
50. Dixon JM, Jane Macaskill E., Endocrine therapy in DCIS: how do we proceed? Breast J. 2012; 18: 295-298.
51. Margolese RG, Cecchini RS, Julian TB, et al., Primary results, NRG Oncology/NSABP B-35: a clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy [abstract]. J Clin Oncol. 2015; 33 (May 20 suppl): LBA500.
52. Silverstein MJ, Lagios MD., Choosing treatment for patients with ductal carcinoma in situ: fine tuning the University of Southern California/Van Nuys Prognostic Index. J Natl Cancer Inst Monogr. 2010; 2010: 193-196.
53. Rudloff U, Jacks LM, Goldberg JI, et al., Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol. 2010; 28: 3762-3769.
54. Solin LJ, Gray R, Baehner FL, et al., A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013; 105: 701-710.
55. Rakovitch E, Nofech-Mozes S, Hanna W, et al., A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat. 2015; 152: 389-398.
56. Alvarado M, Carter DL, Guenther JM, et al., The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: a prospective clinical utility assessment of the 12-gene DCIS Score result. J Surg Oncol. 2015; 111: 935-940.
57. O'Malley FP., Lobular neoplasia: morphology, biological potential and management in core biopsies. Mod Pathol. 2010; 23 (suppl 2): S14-S25.
58. Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ., Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol. 2001; 115: 85-98.
59. Dabbs DJ, Schnitt SJ, Geyer FC, et al., Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol. 2013; 37: e1-e11.
60. Chuba PJ, Hamre MR, Yap J, et al., Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of Surveillance, Epidemiology, and End Results data. J Clin Oncol. 2005; 23: 5534-5541.
61. Pieri A, Harvey J, Bundred N., Pleomorphic lobular carcinoma in situ of the breast: can the evidence guide practice? World J Clin Oncol. 2014; 5: 546-553.
62. National Comprehensive Cancer Network. Breast Cancer Screening and Diagnosis. Version 3. 2015. nccn.org/professionals/physician-gls/pdf/breast-screening.pdf. Accessed September 14, 2015.
63. Claus EB, Stowe M, Carter D., Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. Breast Cancer Res Treat. 2003; 78: 7-15.
64. Sawyer E, Roylance R, Petridis C, et al., Genetic predisposition to in situ and invasive lobular carcinoma of the breast [serial online]. PLoS Genet. 2014; 10: e1004285.
65. Reeves GK, Pirie K, Green J, Bull D, Beral V., Comparison of the effects of genetic and environmental risk factors on in situ and invasive ductal breast cancer. Int J Cancer. 2012; 131: 930-937.
66. Bertrand KA, Tamimi RM, Scott CG, et al., Mammographic density and risk of breast cancer by age and tumor characteristics [serial online]. Breast Cancer Res. 2013; 15: R104.
67. Hwang ES, Miglioretti DL, Ballard-Barbash R, Weaver DL, Kerlikowske K., Association between breast density and subsequent breast cancer following treatment for ductal carcinoma in situ. Cancer Epidemiol Biomarkers Prev. 2007; 16: 2587-2593.
68. Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K., Atypical hyperplasia of the breast-risk assessment and management options. N Engl J Med. 2015; 372: 78-89.
69. Hartmann LC, Radisky DC, Frost MH, et al., Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res (Phila). 2014; 7: 211-217.
70. Luo J, Cochrane BB, Wactawski-Wende J, Hunt JR, Ockene JK, Margolis KL., Effects of menopausal hormone therapy on ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2013; 137: 915-925.
71. Vogel VG, Costantino JP, Wickerham DL, et al., Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials. J Natl Cancer Inst Monogr. 2010; 2010: 181-186.
72. Goss PE, Ingle JN, Ales-Martinez JE, et al., Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011; 364: 2381-2391.
73. Cuzick J, Sestak I, Forbes JF, et al., Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014; 383: 1041-1048.
74. Smith RA, Saslow D, Sawyer KA, et al., American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin. 2003; 53: 141-169.
75. Joslyn SA., Ductal carcinoma in situ: trends in geographic, temporal, and demographic patterns of care and survival. Breast J. 2006; 12: 20-27.
76. Kerlikowske K., Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010; 2010: 139-141.
77. Breen N, Gentleman JF, Schiller JS., Update on mammography trends: comparisons of rates in 2000, 2005, and 2008. Cancer. 2011; 117: 2209-2218.
78. Hofvind S, Skaane P, Elmore JG, Sebuodegard S, Hoff SR, Lee CI., Mammographic performance in a population-based screening program: before, during, and after the transition from screen-film to full-field digital mammography. Radiology. 2014; 272: 52-62.
79. Allison KH, Abraham LA, Weaver DL, et al., Trends in breast biopsy pathology diagnoses among women undergoing mammography in the United States: a report from the Breast Cancer Surveillance Consortium. Cancer. 2015; 121: 1369-1378.
80. Ravdin PM, Cronin KA, Howlader N, et al., The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med. 2007; 356: 1670-1674.
81. Farhat GN, Walker R, Buist DS, Onega T, Kerlikowske K., Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use. J Clin Oncol. 2010; 28: 5140-5146.
82. Li CI, Daling JR, Haugen KL, Tang MT, Porter PL, Malone KE., Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age. Breast Cancer Res Treat. 2014; 145: 481-489.
83. Shamliyan T, Wang SY, Virnig BA, Tuttle TM, Kane RL., Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010; 2010: 121-129.
84. Lari SA, Kuerer HM., Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer. 2011; 2: 232-261.
85. Hu M, Yao J, Carroll DK, et al., Regulation of in situ to invasive breast carcinoma transition. Cancer Cell. 2008; 13: 394-406.
86. Place AE, Jin Huh S, Polyak K., The microenvironment in breast cancer progression: biology and implications for treatment [serial online]. Breast Cancer Res. 2011; 13: 227.
87. Pape-Zambito D, Jiang Z, Wu H, et al., Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients [serial online]. PLoS One. 2014; 9: e100488.
88. Zhou W, Jirstrom K, Amini RM, et al., Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study [serial online]. BMC Cancer. 2013; 13: 512.
89. Siziopikou KP, Anderson SJ, Cobleigh MA, et al., Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. Breast Cancer Res Treat. 2013; 142: 415-421.
90. Rakovitch E, Nofech-Mozes S, Hanna W, et al., [S5-04] A large prospectively-designed study of the DCIS Score: predicting recurrence risk after local excision for ductal carcinoma in situ patients with and without irradiation. Paper presented at: San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, Texas.
91. De Morgan S, Redman S, D'Este C, Rogers K., Knowledge, satisfaction with information, decisional conflict and psychological morbidity amongst women diagnosed with ductal carcinoma in situ (DCIS). Patient Educ Couns. 2011; 84: 62-68.
92. Elmore JG, Ganschow PS, Geller BM., Communication between patients and providers and informed decision making. J Natl Cancer Inst Monogr. 2010; 2010: 204-209.
93. Ganz PA., Quality-of-life issues in patients with ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010; 2010: 218-222.